Elan Corporation, plc (ELN)
-NYSE 12.47 
0.11(0.89%) May 24, 4:04PM EDT|After Hours
:
12.44 0.03 (0.24%) May 24, 4:04PM EDT
| Prev Close: | 12.36 |
|---|
| Open: | 12.38 |
|---|
| Bid: | 12.25 x 1000 |
|---|
| Ask: | 12.70 x 300 |
|---|
| 1y Target Est: | 12.56 |
|---|
| Beta: | 1.25 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 12.36 - 12.55 |
|---|
| 52wk Range: | 9.37 - 14.91 |
|---|
| Volume: | 19,008,470 |
|---|
| Avg Vol (3m): | 6,962,060 |
|---|
| Market Cap: | 6.36B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.07 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Cohen Mulls Plans to Shutter SAC, Open 'Family Shop'at Fox Business(Sat 5:40PM EDT)
- Wohl & Fruchter LLP and Pomerantz Grossman Hufford Dahlstrom & Gross LLP File Consolidated Class Action Complaint on Behalf of Investors in Elan Corporation, plc Alleging Insider Trading by S.A.C. Capital Advisors, L.P. and AffiliatesBusiness Wire(Fri, May 24)
- Elan Rejects Royalty Offer AgainZacks(Fri, May 24)
- InPlay: Elan: Royalty Pharma discloses acceptance levels of original offer for ElanBriefing.com(Fri, May 24)
- Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory RequirementsPR Newswire(Fri, May 24)
- Elan Board Rejects Royalty Pharma's Latest Offerat Motley Fool(Thu, May 23)
- Elan Announces Pricing of US$850 Million in Aggregate Principal Amount of Senior Notes Due 2021Business Wire(Thu, May 23)
- 3 Merger and Acquisitions Stock Stories For a Thursday Appraisalat Wall St. Cheat Sheet(Thu, May 23)
- Alkermes Reports Earnings for Q4Zacks(Thu, May 23)
- Elan board rejects Royalty Pharma's revised tender offerat theflyonthewall.com(Thu, May 23)
- Elan Corporation, plc’s Board of Directors Unanimously Reject Royalty Pharma’s Revised Tender OfferBusiness Wire(Thu, May 23)
- Royalty Pharma Reduces Acceptance Condition to 50% Plus One SharePR Newswire(Thu, May 23)
- Value Investor Seth Klarman's Shakeupsat Motley Fool(Wed, May 22)
- Alkermes Earnings Seen Rising, But Sales Uncertainat Investor's Business Daily(Wed, May 22)
- When Savvy Dealmaking Borders on Reckless Spendingat Motley Fool(Tue, May 21)
Key Statistics
| Forward P/E (1 yr): | 51.96 |
|---|
| P/S (ttm): | 31,520.04 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 0.12 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.01 |
|---|
| Mean Recommendation*: | 2.4 |
|---|
| PEG Ratio (5 yr expected): | 46.82 |
|---|
Business Summary
Elan Corporation, plc operates as a biotechnology company in the United States, Ireland, and internationally. The company primarily develops ELND005, an orally bioavailable small molecule in Phase II clinical trial being investigated for multiple ...
View More